Ashni Logo
Dinesh C. Patel, Ph.D. - Chairman

Dr. Patel is currently Co-founder and Chairman of Salus Therapeutics, Inc., a privately held biotechnology company located in Salt Lake City, Utah, which is focused on the research and development of nucleic acid-based therapeutics, including antisense and gene therapy drugs. Dr. Patel is a Managing Director of vSpring Capital, an early stage venture capital fund. From 1985 - 1999, Dr. Patel served as Co-founder, Chairman of The Board of Directors, President & CEO, of TheraTech, Inc., a Salt Lake City, Utah based company, that has been a pioneer in the development and manufacture of innovative drug delivery products. Under Dr. Patel's guidance, TheraTech established strategic alliances with major pharmaceutical companies including Eli Lilly, Pfizer, Proctor & Gamble, Roche, and SmithKline Beecham. In January 1999, TheraTech was purchased for approximately $350 million by Watson Pharmaceuticals, a California based company. Dr. Patel has been the recipient of numerous awards, including Scientific and Technology Award (State of Utah), and Entrepreneur of the Year Award (Mountain West Venture Group), to name just a few.

John G. Babish, Ph.D.

Dr. Babish is Executive Vice President of Research & Development of Ashni Naturaceuticals. Dr. Babish is a molecular biologist who served as a tenured Associate Professor of Toxicology and Pharmacology at Cornell University for 17 years. In 1991, he pioneered the application of signal transduction technology to the understanding of the mechanism of action of nongenotoxic carcinogens. Dr. Babish has authored or co-authored over one hundred peer-reviewed scientific articles, eight position papers, and two book chapters. He holds nine patents relating to various applications of signal transduction technology and to drugs for infectious and noninfectious diseases. Within the context of his clinical duties at Cornell University, Dr. Babish consulted on the development and FDA approval of three new fluoroguinolone antimicrobials in both human and veterinary medicine. Since 1997 his work has focused on methodology for the formulation of novel complex mixtures of natural bioactive ingredients. Dr. Babish is currently the National Coordinator of the USDA's Minor Use Drug Program that directs research on the safe and effective use of antibiotics in agriculture. He has directed the successful technology transfer activities of three companies from Cornell University and raised in excess of $16 million dollars in these efforts.

James T. O'Brien, B.S.

Mr. O'Brien is the President and Chief Executive Officer of O’Brien Marketing and Communications since September 1996. From 1989 through 1991, he served as President and Chief Operating Officer of Elan Corporation, a pharmaceutical drug delivery company, where he was responsible for worldwide operations and subsidiaries. From 1986 to 1989, Mr. O’Brien was the founding President and Chief Executive Officer of O’Brien Pharmaceuticals. Previously, Mr. O’Brien held several positions with the Revlon Health Care Group, most recently as President of its ethical products division, which included USV Laboratories and the Armour Pharmaceutical Company.

Home || Technology || Product || Management || Press || Board || Contact Us

™Ashni Naturaceuticals, Inc. All rights reserved.